-
Lu Sheng launches the first prospective study of liquid biopsy for lung cancer early screening in the U.S.
Time of Update: 2021-12-02
The project was led by Rajesh Shah, a clinical associate professor at Stanford University, to verify the feasibility of non-invasive liquid biopsy combined with positron emission computed tomography (PET/CT) in high-risk patients to screen for early lung cancer .
-
The clinical study on the functional cure of PD-L1 antibody ASC22 hepatitis B was selected as the "Best Abstract of the Conference" by the Review Committee of the American Association for the Study of Liver Diseases
Time of Update: 2021-12-02
(Hong Kong Stock Exchange code: 1672) today announced its PD-L1 antibody ASC22 (Envolimab) for hepatitis B function The phase IIa and phase IIb clinical studies of sexual cure were selected for the 2021 American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting® 2021) "The Best Abstract Collection-Viral Hepatitis" .
-
Two new crown neutralizing antibody therapies have been approved by the EU to fight the new crown and add new weapons
Time of Update: 2021-12-02
Ronapreve is approved for the treatment of adults and adolescent patients (over 12 years old and weighing at least 40 kg) who do not require supplemental oxygen and are at increased risk of disease deterioration.
-
Results of key clinical trials of TCR cell therapy actively support the submission of regulatory applications next year
Time of Update: 2021-12-02
Today, Adaptimmune Therapeutics announced that its T cell therapy afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), which targets the MAGE-A4 antigen, is used in the treatment of advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) Positive results were obtained in the pivotal phase 2 clinical trial .
-
Does drinking coffee cause heart palpitations?
Time of Update: 2021-12-02
Based on the objective data of ECG monitoring, this study showed that the risk of atrial arrhythmia did not increase overall after drinking coffee, but the risk of premature ventricular contractions increased slightly .
-
New drug for hyperkalemia!
Time of Update: 2021-12-02
S. Food and Drug Administration (FDA) has granted the new oral potassium-lowering drug Lokelma (Liberzol®, generic name: sodium zirconium cyclosilicate, sodium zirconium cyclosilicate) fast track qualification ( FTD): Used for patients with recurrent hyperkalemia (HK) undergoing chronic dialysis to reduce cardiovascular outcomes related to arrhythmia .
-
U.S. FDA allows adults over 18 to receive new crown booster vaccine
Time of Update: 2021-12-02
Specifically, this authorization allows adults over the age of 18 to receive a new crown booster vaccine at least 6 months after completing Moderna or Pfizer/BioNTech's new crown vaccination .
-
New anti-HIV ideas knock on HIV door with drugs to kill infected cells
Time of Update: 2021-12-02
When HIV infects the cell, the sialic acid on the cell surface will begin to look for natural killer (NK) cells that can clear itself, and carry out the corresponding receptors.
-
The new crown is not over yet the new "pig-to-human" coronavirus is coming again
Time of Update: 2021-12-02
Today, a paper published online in the journal Nature adds an even greater uncertainty to the future-in Haiti, scientists have discovered a new type of coronavirus that can infect humans and cause high fevers .
-
Using technology to deliver health, Huisheng's original DHA appeared at the World Omega-3 Technology Conference
Time of Update: 2021-12-02
Xiamen, November 15, 2021/PRNewswire/ - The World Congress of Omega-3 Science & Technology hosted by ISOR in 2021 will be broadcast online from November 13th to 14th . The conference gathered 28
-
The immune system has a "memory" of the coronavirus
Time of Update: 2021-12-02
The team of scientists compared the T cell response of the cohort with medical staff in the control group who were laboratory-confirmed with a new coronavirus infection .
-
61% of patients achieve complete remission, FDA approves the first polycythemia vera interferon drug
Time of Update: 2021-12-02
Recently, PharmaEssentia announced that the US FDA has approved the long-acting interferon Besremi (ropeginterferonα-2b-njft) to be marketed for the treatment of adult patients with polycythemia vera (PV) .
-
First-in-class immune proteasome inhibitor phase II results positive, stock price rose more than 60%
Time of Update: 2021-12-02
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn November 15, Kezar Life Sciences announced the mid-term results of its first-in-class selective immune proteasome inhibitor KZR-616 for the treatment of active, proliferative lupus nephritis (LN) MISSION study phase II trial .
-
So cunning! How do hateful cancer cells invade different types of tissues and organs?
Time of Update: 2021-12-02
Rho/ROCK signal internally controls the meso-scale morphological performance of 3D cultured MDA-MB-231 cellsThe researchers also changed the physical characteristics of ECM from the perspectives of temperature, density, and arrangement, and further understood the deformation and migration of cancer cells.
-
FDA accelerates approval of the first achondroplasia treatment for the root cause of the disease
Time of Update: 2021-12-02
"Reference materials:[1] BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates.
com /2021-11-19-BioMarin-Receives-FDA-Approval-for-VOXZOGO-TM-vosoritide-for-Injection,-Indicated-to-Increase-Linear-Growth-in-Children-with-Achondroplasia-Aged-5- and-Up-with-Open-Growth-Plates
-
Cinda launches PD-1 adjuvant/neo-adjuvant treatment of NSCLC large-scale international multi-center phase III clinical trial
Time of Update: 2021-12-02
On November 12, Cinda Bioregistered and initiated a large international multi-center phase III clinical ORIENT-99 study of sintilimab combined with chemotherapy for preoperative neoadjuvant and postoperative adjuvant treatment of non-small cell lung cancer .
-
Let the lesions "remember", black technology puts "perspective eyes" on doctors
Time of Update: 2021-12-02
Next, the team of Zhang Xiangtong and Liang Hongsheng performed 3D modeling and algorithm optimization in the "Medical Artificial Intelligence Laboratory" based on the original CT and magnetic resonance imaging data, and gave targeted positioning for the lesion .
-
Palmitic acid in the diet increases the risk of cancer spreading
Time of Update: 2021-12-02
According to the results of the study, a diet lacking palmitic acid can effectively slow the metastasis process, but more work needs to be done to determine this .
-
Acquired 4 targeted therapies including TIGIT antibody and Gilead to expand its oncology pipeline for US$725 million
Time of Update: 2021-12-02
Today, Gilead Sciences and Arcus Biosciences jointly announced that Gilead has exercised its option to obtain multiple R&D projects in Arcus’ clinical R&D pipeline, including two monoclonal antibodies domvanalimab and AB308 that target TIGIT, and small Molecular therapy etrumadenant and quemliclustat .
-
Why is the efficacy of new anti-cancer drugs limited?
Time of Update: 2021-12-02
By comparing tumor samples before and after treatment with sotorasib, the research team found that in the 27 resistant patients, many genes had additional mutations, including NRAS, BRAF, EGFR, and MYC, which have been found in a variety of cancer types Has a cancer-promoting effect .
Retrieved Nov 12th, 2021 from https:// patients-develop-resistance-landmark-lung-cancer-drug[2] First Ever KRAS Inhibitor Approved for Non-Small Cell Lung Cancer.
